Retraction to: Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension: RKIP and pulmonary hypertension (British Journal of Pharmacology, (2011), 163, 5, (948-963), 10.1111/j.1476-5381.2011.01305.x);Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension

British Journal of Pharmacology

Volumn 163, Issue 5, 2011, Pages 948-963

  Morecroft, I ^a   Doyle, B ^b   Nilsen, M ^a   Kolch, W ^c   Mair, K ^a   MacLean, M R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

5 HT transporter; hypoxia; pulmonary hypertension; RKIP

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGENIC AGENT; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GENE DELETION; HYPOXIA; IN VITRO STUDY; LUNG ARTERY; LUNG FIBROBLAST; LUNG HEMODYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

EID: 79958845053     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13796     Document Type: Erratum

References (44)

1. Chin KM, Rubin LJ, (2008). Pulmonary arterial hypertension. J Am Coll Cardiol 51: 1527-1538. (Pubitemid 351508372)
2. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR, (2003). Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 278: 13061-13068. (Pubitemid 36800074)
3. Das M, Bouchey DM, Moore MJ, Hopkins DC, Nemenoff RA, Stenmark KR, (2001). Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on g protein-mediated activation of mitogen-activated protein kinases. J Biol Chem 276: 15631-15640.
4. van Dijk MC, Hilkmann H, van Blitterswijk WJ, (1997). Platelet-derived growth factor activation of mitogen-activated protein kinase depends on the sequential activation of phosphatidylcholine-specific phospholipase C, protein kinase C-zeta and Raf-1. Biochem J 325 (Pt 2): 303-307. (Pubitemid 27338706)
5. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, et al,. (2006). Cross talk between endothelial and smooth muscle cells in pulmonary hypertension-critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113: 1857-1864. (Pubitemid 43739397)
6. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al,. (1990). Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294.
7. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, et al,. (2008). An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118: 1846-1857. (Pubitemid 351632387)
8. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ, (2004). Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110: 718-723. (Pubitemid 39056272)
9. Huang J, Mahavadi S, Sriwai W, Grider JR, Murthy KS, (2007). Cross-regulation of VPAC(2) receptor desensitization by M(3) receptors via PKC-mediated phosphorylation of RKIP and inhibition of GRK2. Am J Physiol Gastrointest Liver Physiol 292: G867-G874. (Pubitemid 46442639)
10. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH, et al,. (2000). Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 23: 593-601.
11. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR, (2001). Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension-converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res 89: 1231-1239. (Pubitemid 34627883)
12. Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, et al,. (2009). Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53: 877-883.
13. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, et al,. (2008). Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118: 2081-2090.
14. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, et al,. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81-84.
15. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, et al,. (2005). Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97: 227-235. (Pubitemid 41105448)
16. Lee SL, Wang WW, Finlay GA, Fanburg BL, (1999). Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277: L282-L291. (Pubitemid 29415085)
17. Liu Y, Li M, Warburton RR, Hill NS, Fanburg BL, (2007). The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 21: 2725-2734. (Pubitemid 47372740)
18. Liu YL, Suzuki YJ, Day RM, Fanburg BL, (2004). Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95: 579-586. (Pubitemid 39274372)
19. Lorenz K, Lohse MJ, Quitterer U, (2003). Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426: 574-579. (Pubitemid 37522645)
20. Ma J, Li F, Liu L, Cui D, Wu X, Jiang X, et al,. (2009). Raf kinase inhibitor protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells. Liver Int 29: 567-574.
21. MacLean MR, Dempsie Y, (2009). Serotonin and pulmonary hypertension-from bench to bedside? Curr Opin Pharmacol 9: 281-286.
22. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen SB, Sheward J, et al,. (2004). Overexpression of the 5-hydroxytryptamine transporter gene-effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109: 2150-2155. (Pubitemid 38620226)
23. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM, (2008). Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155: 606-616.
24. Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, et al,. (2004). Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94: 1263-1270. (Pubitemid 38656414)
25. Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR, (1999). 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128: 730-734. (Pubitemid 29504766)
26. Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J, et al,. (2005). Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313: 539-548. (Pubitemid 40604152)
27. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, et al,. (2007). Effect of Tryptophan Hydroxylase 1 Deficiency on the Development of Hypoxia-Induced Pulmonary Hypertension. Hypertension 49: 232-236. (Pubitemid 46360365)
28. Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y, et al,. (2010). In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 85: 593-603.
29. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, et al,. (2008). Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 33: 278-291. (Pubitemid 351629535)
30. Murray F, MacLean MR, Pyne NJ, (2003). An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension. Br J Pharmacol 138: 1313-1319. (Pubitemid 36543129)
31. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al,. (2008). Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88. (Pubitemid 351919196)
32. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, et al,. (2007). A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 132: 1265-1274. (Pubitemid 47621003)
33. Short M, Fox S, Stenmark KR, Das M, (2005). Hypoxia-induced alterations in protein kinase C zeta signaling result in augmented fibroblast proliferation. Chest 128: 582S. (Pubitemid 43054138)
34. Tang H, Park S, Sun SC, Trumbly R, Ren G, Tsung E, et al,. (2010). RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Lett 584: 662-668.
35. Theroux S, Pereira M, Casten KS, Burwell RD, Yeung KC, Sedivy JM, et al,. (2007). Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit. Brain Res Bull 71: 559-567. (Pubitemid 46209521)
36. Welsh DJ, Harnett M, MacLean M, Peacock AJ, (2004). Proliferation and signaling in fibroblasts-role of 5-hydroxytryptamine(2A) receptor and transporter. Am J Respir Crit Care Med 170: 252-259. (Pubitemid 38971409)
37. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR, (2011a). The serotonin transporter, gender, and 17{beta} oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res (in press; doi: 10.1093/cvr/cvq408).
38. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, et al,. (2011b). The serotonin transporter, gender and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics (in press; doi:10.1152/physiolgenomics.00249.2010).
39. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A, et al,. (2008). Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells. Implications for familial pulmonary arterial hypertension. Circ Res 102: 1212-1221.
40. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, et al,. (2005). Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96: 1053-1063. (Pubitemid 40791377)
41. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al,. (1999). Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177. (Pubitemid 29436321)
42. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, et al,. (2000). Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20: 3079-3085. (Pubitemid 30215020)
43. Yu L, Quinn DA, Garg HG, Hales CA, (2006). Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 345: 1565-1572. (Pubitemid 43817908)
44. Zhu S, Mc Henry KT, Lane WS, Fenteany G, (2005). A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol 12: 981-991. (Pubitemid 41338808)